299 related articles for article (PubMed ID: 26555301)
1. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
3. Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor.
Stsiapanava A; Olsson U; Wan M; Kleinschmidt T; Rutishauser D; Zubarev RA; Samuelsson B; Rinaldo-Matthis A; Haeggström JZ
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4227-32. PubMed ID: 24591641
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
[TBL] [Abstract][Full Text] [Related]
5. Capturing LTA
Stsiapanava A; Samuelsson B; Haeggström JZ
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9689-9694. PubMed ID: 28827365
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the 5-Lipoxygenase Pathway by Chalcogen-Containing Inhibitors of Leukotriene A
Teder T; König S; Singh R; Samuelsson B; Werz O; Garscha U; Haeggström JZ
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108702
[TBL] [Abstract][Full Text] [Related]
7. A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.
Poras H; Duquesnoy S; Fournié-Zaluski MC; Ratinaud-Giraud C; Roques BP; Ouimet T
Anal Biochem; 2013 Oct; 441(2):152-61. PubMed ID: 23851339
[TBL] [Abstract][Full Text] [Related]
8. Effect of Modifier Structure on the Activation of Leukotriene A
Lee KH; Petruncio G; Shim A; Burdick M; Zhang Z; Shim YM; Noble SM; Paige M
J Med Chem; 2019 Dec; 62(23):10605-10616. PubMed ID: 31751136
[TBL] [Abstract][Full Text] [Related]
9. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, docking, cytotoxicity, and LTA
El-Naggar MH; Mira A; Abdel Bar FM; Shimizu K; Amer MM; Badria FA
Bioorg Med Chem; 2017 Feb; 25(3):1277-1285. PubMed ID: 28065501
[TBL] [Abstract][Full Text] [Related]
11. The development of novel LTA
Low CM; Akthar S; Patel DF; Löser S; Wong CT; Jackson PL; Blalock JE; Hare SA; Lloyd CM; Snelgrove RJ
Sci Rep; 2017 Mar; 7():44449. PubMed ID: 28303931
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.
Karami L; Saboury AA; Rezaee E; Tabatabai SA
Eur Biophys J; 2017 Jul; 46(5):445-459. PubMed ID: 27928588
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation.
Thunnissen MM; Nordlund P; Haeggström JZ
Nat Struct Biol; 2001 Feb; 8(2):131-5. PubMed ID: 11175901
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Evaluation of diaryl ether modulators of the leukotriene A
Petruncio G; Lee KH; Girgis M; Shellnutt Z; Beaulac Z; Xiang J; Lee SH; Peng X; Burdick M; Noble SM; Shim YM; Paige M
Eur J Med Chem; 2024 Jun; 272():116459. PubMed ID: 38704942
[TBL] [Abstract][Full Text] [Related]
15. Thermodynamic properties of leukotriene A
Wittmann SK; Kalinowsky L; Kramer JS; Bloecher R; Knapp S; Steinhilber D; Pogoryelov D; Proschak E; Heering J
Bioorg Med Chem; 2016 Nov; 24(21):5243-5248. PubMed ID: 27651294
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design.
Thangapandian S; John S; Arooj M; Lee KW
PLoS One; 2012; 7(4):e34593. PubMed ID: 22496831
[TBL] [Abstract][Full Text] [Related]
17. QM/MM Molecular Dynamics Investigations of the Substrate Binding of Leucotriene A4 Hydrolase: Implication for the Catalytic Mechanism.
Mu X; Xu D
J Phys Chem B; 2018 Jul; 122(29):7253-7263. PubMed ID: 29965770
[TBL] [Abstract][Full Text] [Related]
18. In silico modeling of the molecular structure and binding of leukotriene A4 into leukotriene A4 hydrolase.
Paz PB; Vega-Hissi EG; Estrada MR; Garro Martinez JC
Chem Biol Drug Des; 2012 Dec; 80(6):902-8. PubMed ID: 22913921
[TBL] [Abstract][Full Text] [Related]
19. Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: implications for M1 aminopeptidases and inhibitor design.
Tholander F; Muroya A; Roques BP; Fournié-Zaluski MC; Thunnissen MM; Haeggström JZ
Chem Biol; 2008 Sep; 15(9):920-9. PubMed ID: 18804029
[TBL] [Abstract][Full Text] [Related]
20. Structural origins for the loss of catalytic activities of bifunctional human LTA4H revealed through molecular dynamics simulations.
Thangapandian S; John S; Lazar P; Choi S; Lee KW
PLoS One; 2012; 7(7):e41063. PubMed ID: 22848428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
